Published in JAMA · View the paper (DOI)
A randomized trial found fluvoxamine significantly reduces the risk of worsening symptoms like pneumonia and oxygen desaturation in adult outpatients with mild COVID-19. The study also suggests fluvoxamine's potential as a treatment for COVID-19, offering hope for improved patient outcomes.
Coverage from 2 institutions